The Food and Drug Administration (FDA) has added new warnings to popular diabetes drugs containing saxagliptin and alogliptin. This came after a safety review showed an increase in the risk of heart failure in patients who already suffer from kidney and heart disease. The drugs containing these ingredients are sold under the following brand names:
• Onglyza, Kombiglyze XR, manufactured and sold by AstraZeneca; and
• Nesina, Kazano, and Oseni, all manufactured and sold by Takeda Pharmaceuticals.
Each of the drugs are relatively new to the market and are intended to lower the blood sugar and HbA1c levels by triggering the pancreas to release more insulin after Type-2 diabetics eat their meals. Takeda – no stranger to litigation as a result of bladder cancer being caused by their diabetes drug Actos – intended Nesina to be the first DPP-4 drug to be released in the U.S. However, because the FDA issued stricter cardiovascular safety requirements, Takeda was forced to conduct new safety trials before the drug was approved in 2013.
Type-2 diabetes can be a deadly disease if untreated or inadequately treated, and it affects millions of Americans. However, in some instances, patients can reverse Type-2 diabetes by making significant lifestyle changes including a healthy diet and exercise. It is also important to remember that pharmaceutical giants like these two companies are all vying to obtain their share of the multi-billion dollar industry. As a result, rushing drugs to market by the drug companies with little safety and efficacy data is now all too common.
If you need more information on this subject, contact Matt Munson, a lawyer in our firm’s Mass Torts Section, at 800-898-2034 or by email at Matt.Munson@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.